Table 1.
Clinical trials involving combination treatment targeting cancer stem cells to overcome chemo- and radioresistance.
| Tumor type | Clinical trial ID | Drug targeting CSC (plus chemo/radiotherapy) |
|---|---|---|
| Breast | NCT02876302; NCT02776917; NCT02370238; NCT01868503; NCT01876251; NCT02001974; NCT01372579; NCT01281163; NCT01190345; NCT01118975; NCT00949247; NCT00645333; NCT00524303 | Ruxolitinib; cirmtuzumab; reparixin; lapatinib; PF-03084014; eribulin mesylate; MK2206; bevacizumab; vorinostat; MK0752; trastuzumab |
| Pancreatic | NCT022311723; NCT01195415; NCT01192763; NCT01189929; NCT01051284 | BBI608; vismodegib; RO4929097; demcizumab; cyberknife radiation |
| Ovarian | NCT03632798; NCT03030287; NCT02713386; NCT01579812 | Avastin; OMP-305B83; ruxolitinib; metformin |
| Hematologic | NCT03113643; NCT02730195; NCT01861340; NCT01130688 | Azacitidine; pioglitazone; MEDI-551; zileuton |
| Glioma | NCT03632135; NCT02315534; NCT02039778; NCT01119599 | Vincristine; irinotecan; etoposide; imatinib; BBI608; stem cell radiotherapy; RO4929097 |
| Colorectal | NCT03035253; NCT02753127; NCT01189942 | OMP-305B83; BBI608; OMP-21M18 |
| Non-small-cell lung | NCT01193868; NCT01189968 | RO4929097; demcizumab |
| Hepatocellular | NCT02279719; NCT01442870 | BBI503; BBI608; metformin |
| Esophageal | NCT02423811 | Fursultiamine |
| Gastrointestinal | NCT02024607 | BBI608 |
| Head and neck | NCT01255800 | IPI-926 |
| Advanced or metastatic | NCT02722954; NCT02483247; NCT02467361; NCT02432326 | Demcizumab; BBI503; BBI608 |